Science

We are pioneering a next generation approach by modifying saRNA to modulate the innate immune response thereby overcoming current limitations
RNA therapeutics have emerged as a new modality for treating life threatening conditions and combating serious infections. Acting as the ‘software’ that programmes the body’s own cells to manufacture proteins or antigens, to which the immune system responds to generate immunity.
Virus 80
First-generation mRNA vaccines have been successfully used to combat the COVID-19 pandemic. The first-generation mRNA vaccines have been successfully used to combat the COVID-19 pandemic. However, the impact and reach of these vaccines and therapeutics may be limited by tolerability, cost of goods and stability. Modulating the immune response and better matching the delivery modality can improve tolerability, enable lower doses, minimize cost of goods and improve stability.
VaxEquity is focused on modulating the body’s innate immune response to suppress the degradation of RNA therapeutic effect.

Our innovative self-amplifying RNA platform has the ability to enable more durable protein expression and hence create an improved therapeutic effect.

Technology platform

Get in touch

Thank you for your message

We have recieved your message and will get back to your shortly.